These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 22882755)
1. Clinical and psychosocial remission in schizophrenia: correlations with antipsychotic treatment. Barak Y; Aizenberg D BMC Psychiatry; 2012 Aug; 12():108. PubMed ID: 22882755 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study. Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986 [TBL] [Abstract][Full Text] [Related]
3. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596 [TBL] [Abstract][Full Text] [Related]
4. Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment. Lambert M; De Marinis T; Pfeil J; Naber D; Schreiner A Eur Psychiatry; 2010 May; 25(4):220-9. PubMed ID: 19926263 [TBL] [Abstract][Full Text] [Related]
5. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists]. Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914 [TBL] [Abstract][Full Text] [Related]
6. Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months. Llorca PM; Sacchetti E; Lloyd K; Kissling W; Medori R Int J Clin Pharmacol Ther; 2008 Jan; 46(1):14-22. PubMed ID: 18218293 [TBL] [Abstract][Full Text] [Related]
8. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients. Taylor DM; Young CL; Mace S; Patel MX J Clin Psychiatry; 2004 Aug; 65(8):1076-83. PubMed ID: 15323592 [TBL] [Abstract][Full Text] [Related]
9. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder. Rossi A; Bagalà A; Del Curatolo V; Scapati F; Bernareggi MM; Giustra MG; Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173 [TBL] [Abstract][Full Text] [Related]
10. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable. Rosa F; Schreiner A; Thomas P; Sherif T Clin Drug Investig; 2012 Apr; 32(4):267-79. PubMed ID: 22339430 [TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa A; Goldfinger SM J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343 [TBL] [Abstract][Full Text] [Related]
12. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea. Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566 [TBL] [Abstract][Full Text] [Related]
13. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens. Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197 [TBL] [Abstract][Full Text] [Related]
14. Symptomatic remission in elderly schizophrenia patients treated with long-acting risperidone. Tadger S; Baruch Y; Barak Y Int Psychogeriatr; 2008 Dec; 20(6):1245-50. PubMed ID: 18620626 [TBL] [Abstract][Full Text] [Related]
15. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J Int Clin Psychopharmacol; 2008 Nov; 23(6):325-31. PubMed ID: 18854720 [TBL] [Abstract][Full Text] [Related]
16. Remission in schizophrenia: critical and systematic review. AlAqeel B; Margolese HC Harv Rev Psychiatry; 2012; 20(6):281-97. PubMed ID: 23216066 [TBL] [Abstract][Full Text] [Related]
17. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. Fleischhacker WW; Eerdekens M; Karcher K; Remington G; Llorca PM; Chrzanowski W; Martin S; Gefvert O J Clin Psychiatry; 2003 Oct; 64(10):1250-7. PubMed ID: 14658976 [TBL] [Abstract][Full Text] [Related]
18. Remission and employment status in schizophrenia and other psychoses: One-year prospective study in Croatian patients treated with risperidone long acting injection. Mihaljevic-Peles A; Sagud M; Filipcic IS; Grosic V; Pedisic I; Emsley R Psychiatr Danub; 2016 Sep; 28(3):263-272. PubMed ID: 27658835 [TBL] [Abstract][Full Text] [Related]
19. Influence of antipsychotic treatment type and regimen on the functionality of patients with schizophrenia. Acosta FJ; Chinea E; Hernández JL; Rodríguez F; García-Bello M; Medina G; Nieves W Nord J Psychiatry; 2014 Apr; 68(3):180-8. PubMed ID: 23672274 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK. Tempest M; Sapin C; Beillat M; Robinson P; Treur M J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]